Skip to Content

Clinical Trial Details

Dasatinib Use in Recurrent Brain Cancer

A Phase I/Randomized Phase II Double-Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma

Objective

Must have measurable disease. Must have completeed radiation treatment at least 12 weeks before study enrollment. Can have had up to two other chemotherapy programs.

Exclusion Criteria
Uncontrolled blood pressure in not allowed

IRB Protocol Number
NCCTG N0872

Clinical Trial Categories

  • Brain Cancer
Contact
Margaret White, RN OCN, CC at 603-232-8908

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000